This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lu, M.
Right arrow Articles by Shen, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lu, M.
Right arrow Articles by Shen, S.

 Previous Article  |  Next Article 

Journal of Virology, May 1999, p. 4433-4438, Vol. 73, No. 5
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Subdomain Folding and Biological Activity of the Core Structure from Human Immunodeficiency Virus Type 1 gp41: Implications for Viral Membrane Fusion

Min Lu,* Hong Ji, and Steven Shen

Department of Biochemistry, Weill Medical College of Cornell University, New York, New York 10021

Received 9 September 1998/Accepted 5 January 1999


    ABSTRACT
Top
Abstract
Text
References

The envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1) consists of two subunits, gp120 and gp41. The extraviral portion (ectodomain) of gp41 contains an alpha -helical domain that likely represents the core of the fusion-active conformation of the molecule. Here we report the identification and characterization of a minimal, autonomous folding subdomain that retains key determinants in specifying the overall fold of the gp41 ectodomain core. This subdomain, designated N34(L6)C28, is formed by covalent attachment of peptides N-34 and C-28 by a short flexible linker in place of the normal disulfide-bonded loop sequence. N34(L6)C28 forms a highly thermostable, alpha -helical trimer. Point mutations within the envelope protein complex that abolish membrane fusion and HIV-1 infectivity also impede the formation of the N34(L6)C28 core. Moreover, N34(L6)C28 is capable of inhibiting HIV-1 envelope-mediated membrane fusion. Taken together, these results indicate that the N34(L6)C28 core plays a direct role in the membrane fusion step of HIV-1 infection and thus provides a molecular target for the development of antiviral pharmaceutical agents.


    TEXT
Top
Abstract
Text
References

Viral envelope glycoprotein-mediated membrane fusion is an essential step in the infectious processes of all enveloped animal viruses, including human pathogens such as influenza virus and human immunodeficiency virus type 1 (HIV-1). The envelope glycoprotein of HIV-1 is first synthesized as a polypeptide precursor, gp160, which is then posttranslationally processed to generate two noncovalently associated subunits, gp120 and gp41 (19, 28, 29). gp120 recognizes the target cell by binding to the CD4 glycoprotein and a chemokine receptor (13, 24, 32, 42). gp41 then undergoes conformational changes to become active in promoting virus-cell membrane fusion, a process that leads to viral entry and infection of cells. These conformational changes are thought to be involved in the transition in gp41 from a native (nonfusogenic) to a fusion-active (fusogenic) state (reviewed in reference 7).

The extraviral portion (ectodomain) of the gp41 molecule is directly involved in the membrane fusion process (29). The amino terminus of gp41 contains a hydrophobic, glycine-rich sequence referred to as the fusion peptide that is essential for membrane fusion. There are two 4-3 hydrophobic (heptad) repeat sequences within the gp41 ectodomain which are predicted to form coiled coils, as seen in most viral fusion proteins (6, 12, 16). The N (amino)-terminal heptad repeat is located adjacent to the fusion peptide, while the C (carboxyl)-terminal heptad repeat precedes the transmembrane segment. Limited proteolysis of a fragment corresponding to the gp41 ectodomain led to the identification of a soluble, alpha -helical complex consisting of a trimer of antiparallel dimers (26, 27). Biophysical studies suggest that three N-terminal helices form an interior, parallel-coiled-coil trimer, while three C-terminal helices pack in the reverse direction into three hydrophobic grooves on the surface of this coiled coil (27). Crystallographic analysis of the gp41 ectodomain core confirmed that it folds into a six-helix bundle (Fig. 1B) (8, 34, 35). A number of studies support the notion that this six-helix structure represents the fusion-active conformation of the gp41 ectodomain core (8, 15, 20, 23, 27, 30, 34, 35).


View larger version (33K):
[in this window]
[in a new window]
  		FIG. 1.   An alpha -helical core subdomain within the ectodomain of HIV-1 gp41. (A) Schematic representation of gp41. The important functional features of the gp41 ectodomain, the locations of the N-36 and C-34 peptides, and the amino acid sequences of the N-34 and C-28 peptides are shown. N34(L6)C28 consists of N-34 and C-28 plus a linker of six hydrophilic residues. The disulfide bond and four potential N-glycosylation sites are depicted. The residues are numbered according to their position in gp160. (B) Ribbon diagram of the N34(L6)C28 core. The N-terminal helices are depicted in yellow, and the C-terminal helices are in purple. The N-34 and C-28 termini are joined by a linker. The left panel shows an end-on view of N34(L6)C28 looking down the three-fold axis of the trimer. The right panel shows a side view of the N34(L6)C28 trimer.

We report here the identification and characterization of a small subdomain that dictates the folding and stability of the gp41 core from the HIV-1 envelope protein. This subdomain, designated N34(L6)C28, consists of two highly truncated peptides, N-34 and C-28, which are connected by a six-residue hydrophilic linker (Fig. 1A). N34(L6)C28 forms an alpha -helical, discrete trimer. Moreover, our data on the in vitro folding of the trimeric N34(L6)C28 complex correlate well with the severity of the in vivo phenotypes observed in cells expressing the full-length HIV-1 envelope protein (14). Finally, N34(L6)C28 can inhibit HIV-1-mediated membrane fusion at micromolar concentrations. These results provide evidence that the core structure formed by N34(L6)C28 plays a direct role in the HIV-1 fusion events.

The N34(L6)C28 subdomain. Previous studies identified an alpha -helical complex within the gp41 ectodomain consisting of the peptides N-36 and C-34 and showed that these two peptides associate to form a stable, alpha -helical trimer of heterodimers (Fig. 1A) (26). To facilitate further studies, we designed and constructed a unimolecular (i.e., single-chain) analog for the N-36 and C-34 complex, in which the C terminus of N-36 is connected to the N terminus of C-34 by the hydrophilic linker Ser-Gly-Gly-Arg-Gly-Gly. Plasmid pN36/C34(L6), encoding this unimolecular model designated N36(L6)C34, was constructed by single-strand mutagenesis of pN41/C34(L6) (26). N36(L6)C34 and variants thereof were expressed in Escherichia coli BL21(DE3)/pLysS by using the T7 expression system as previously described (26). Proteins were purified to homogeneity by reverse-phase high-performance liquid chromatography as previously described (26). Protein identity was confirmed by mass spectrometry.

Circular dichroism (CD) spectra were measured with an AVIV 62DS CD spectrometer as previously described (26). Thermal stability was determined by monitoring the change in CD signal at 222 nm as a function of temperature. The midpoint of the thermal unfolding transition (apparent Tm) was determined from the maximum of the first derivative, with respect to the reciprocal of the temperature, of the [theta ]222 values. The error in estimation of Tm was ±1°C. Apparent molecular weights were determined by sedimentation equilibrium with a Beckman XL-A analytical ultracentrifuge as previously described (26). Data sets (six per peptide) were fitted simultaneously to a single-species model with the program NONLIN (22) to yield an apparent sigma  value. Specific volumes and solvent densities were calculated as described by Laue et al. (25).

The CD spectrum of N36(L6)C34 is typical of an alpha -helix, displaying the characteristic minima at 208 and 222 nm. From the magnitude of the CD signal at 222 nm (Table 1), we estimate that 60 residues (~85% helix content) are in alpha -helical conformation. This helical structure is remarkably stable; at a neutral pH and a 10 µM protein concentration, the apparent Tm of N36(L6)C34 is 79°C (Table 1). Sedimentation equilibrium experiments showed that the apparent molecular weight of N36(L6)C34 changes with peptide concentration, indicating that N36(L6)C34 tends to aggregate in solution (data not shown).

                              
View this table:
[in this window]
[in a new window]
  		TABLE 1.   Summary of CD and sedimentation equilibrium data for the gp41 model peptides

To trim unfolded regions that potentially contribute to the aggregation, N36(L6)C34 was subjected to limited proteolysis as previously described (26). The peptide fragments were separated and purified by high-performance liquid chromatography, and each peptide was then identified by N-terminal sequencing and mass spectrometry. Five residues at the N terminus of each identified proteolytic fragment were sequenced. Digestion with proteinase K yielded, in addition to N-36 (residues 546 to 581) (observed mass, 4,123 Da; expected, 4,123 Da) and C-34 (residues 628 to 661) with the N-terminal sequence Ser-Gly-Gly-Arg-Gly-Gly (observed mass, 4,721 Da; expected, 4,720 Da), two shorter peptide fragments: C-25, spanning residues 628 to 652 with the N-terminal sequence Ser-Gly-Gly-Arg-Gly-Gly (observed mass, 3,609 Da; expected, 3,608 Da), and N36(L6)C25, spanning residues 546 to 581 (N-36) and 628 to 652 (C25) connected by the linker Ser-Gly-Gly-Arg-Gly-Gly (observed mass, 7,713 Da; expected, 7,713 Da). Digestion of N36(L6)C34 with trypsin generates, in addition to N-36 (residues 546 to 581) with the C-terminal sequence Ser-Gly-Gly-Arg (observed mass, 4,481 Da; expected, 4,480 Da) and C-34 (residues 628 to 661) with the N-terminal sequence Gly-Gly (observed mass, 4,364 Da; expected, 4,363 Da), two shorter peptide fragments: N-34, spanning residues 546 to 579 (observed mass, 3,897 Da; expected, 3,897 Da), and C-28, spanning 628 to 655 with the N-terminal sequence Gly-Gly (observed mass, 3,634 Da; expected, 3,636 Da). The C terminus of N36(L6)C34 is trimmed to Gln 652 with proteinase K or to Lys 655 with trypsin. Trypsin also cleaves N36(L6)C34 at Arg 579. These results indicate that the C-terminal regions of both the helical segments in N36(L6)C34 are not well folded. Accordingly, we adopted the peptides N-34 and C-28 for further studies.

We produced a bacterially expressed single-chain model, designated N34(L6)C28, for the N-34 and C-28 complex. In this molecule, the C terminus of N-34 is connected to the N terminus of C-28 by the linker Ser-Gly-Gly-Arg-Gly-Gly. CD spectra show that N34(L6)C28 is fully helical (Table 1) and highly stable against thermal denaturation, with an apparent Tm of 70°C (10 µM and pH 7.0) under physiological conditions (Table 1). Over a 10-fold range of protein concentrations, the apparent molecular mass of N34(L6)C28 is 24.4 kDa, as determined by sedimentation equilibrium (Table 1). This value, compared to the expected molecular mass of 23.6 kDa for a trimer, indicates that N34(L6)C28 is trimeric in solution.

To examine if the sequence and/or length of the peptide linker per se affects the N-34 and C-28 complex formation, we produced two additional single-chain models with linkers that vary in sequence and length. The two helical segments are connected by the linker Gly-Pro-Arg-Arg-Gly in N34(L5)C28 or by (Gly-Pro-Arg-Arg-Gly)2 in N34(L10)C28. CD spectra indicate that both the model peptides exist in fully helical conformations which sedimentation equilibrium indicates is a clean trimer (Table 1). Therefore, the linker in N34(L6)C28 appears to stabilize the folded gp41 core for entropic reasons, without perturbing its structure.

To address whether N34(L6)C28 is the smallest cooperatively folded subdomain, we truncated four residues (Leu 576, Gln 577, Ala 578, and Arg 579) from the C-terminal sequence of the N-34 segment in N34(L6)C28 (Fig. 2A). This truncation was chosen for the investigation of how the formation of the central, alpha -helical coiled-coil interactions gives rise to the cooperative folding and stability of N34(L6)C28. N30(L6)C28 corresponds to a deletion of residues 576 to 579 and was produced in bacteria. Its CD spectrum indicates that N30(L6)C28 is only approximately two-thirds helical, with an apparent Tm of 39°C for a 10 µM solution (Fig. 2B). Moreover, equilibrium sedimentation shows that the radial distribution of N30(L6)C28 is nonlinear and becomes progressively more curved as the concentration is increased, indicating that the peptide in solution forms a mixture of oligomeric species (data not shown). Taken together, these results indicate that N30(L6)C28 is unable to impart the structural specificity conferred by N34(L6)C28. It is likely that the loss of favorable homotrimeric interactions around Leu 576 results in the destabilization of the central, trimeric coiled coil, and therefore contributes to the "misfolding" of N30(L6)C28. Indeed, the CD spectrum indicates that the isolated N-34 peptide contains an ~90% alpha -helical structure, while the isolated N-30 peptide is largely unfolded (Fig. 2A). Thus, the N-34 peptide seems to be the shortest N-terminal heptad-repeat sequence required to specify the overall fold of the stable core structure of the gp41 ectodomain. By extension, N34(L6)C28 may represent the smallest stable, cooperatively folded gp41 core.


View larger version (23K):
[in this window]
[in a new window]
  		FIG. 2.   (A) Sequences of the N-34 and N-30 peptides, with the heptad positions marked above the sequence. (B) CD spectra of N30(L6)C28 (10 µM) (filled circles), N-34 (50 µM) (open triangles), and N-30 (50 µM) (open circles) in PBS at 0°C. (C) Temperature dependence of the CD signal at 222 nm for N30(L6)C28 (10 µM) (filled circles), N-34 (50 µM) (open triangles), and N-30 (50 µM) (open circles) in PBS.

A folding defect in N34(L6)C28 arises from fusion-defective mutations of gp120-gp41. Ile 573, located at an a heptad position in the coiled coil, forms a homotrimeric packing at the center of the coiled coil and interacts with Trp 631 of the C-terminal helix in the crystal structure of the gp41 core (Fig. 3A) (8, 34, 35). Mutagenesis studies show that the hydrophobicity of the side chain at the conserved Ile 573 site is coupled to the fusion activity of the HIV-1 envelope protein complex (14). To understand how these mutations affect gp41 core structure formation, we substituted Ile 573 in N34(L6)C28 with Leu, Val, Ala, Ser, and Pro to generate five mutants. Peptides with conservative mutations (I573L and I573V) were expressed in E. coli at high levels (~50 mg of protein per liter of culture), while peptide expression was limited to ~6 mg per liter for I573A and 1 mg per liter for I573S and I573P.


View larger version (17K):
[in this window]
[in a new window]
  		FIG. 3.   Helical structure and thermal stability of the N34(L6)C28 mutant peptides. (A) Helix packing in the hydrophobic layer between Gly 572 and Ile 573 in the interior coiled-coil trimer and Trp 631 and Asp 632 in the outside C-terminal helices. (B) CD spectra of the N34(L6)C28 mutant peptides (10 µM) (I573L, filled triangles; I573V, open circles; I573A, filled circles; I573S, open rhombs; I573P, open triangles) in PBS at 0°C. (C) Temperature dependence of the CD signal at 222 nm for the N34(L6)C28 mutant peptides (10 µM) (I573L, filled triangles; I573V, open circles; I573A, filled circles; I573S, open rhombs; I573P, open triangles) in PBS.

CD spectra of the I573L and I573V mutants indicate that the folded mutant peptides exhibit a >95% alpha -helical structure (Fig. 3A and Table 2). At a neutral pH and a 10 µM peptide concentration, the apparent Tms of I573L and I573V are 67 and 65°C, respectively (Fig. 3B and Table 2). Sedimentation equilibrium experiments indicate that both I573L and I573V form clean trimers in solution (Table 2). In contrast, the I573S and I573P mutants form insoluble aggregates at concentrations above ~10 µM in phosphate-buffered saline (PBS). These mutant peptides are much less helical than the wild-type peptide (approximately 100% helix content for wild type, 42% for I573S, and 48% for I573P) (Fig. 3B and Table 2). The structures of I573S and I573P also unfold at much lower apparent Tms (70°C for wild type, 25°C for I573S, and 24°C for I573P) (Fig. 3C and Table 2). An intermediate effect is seen in the I573A peptide, which contains an ~77% alpha -helical structure, with an apparent Tm of 37°C (Fig. 3B and C and Table 2). Equilibrium sedimentation of the I573A mutant yielded average molecular masses consistent with a clean trimer (Table 2). These results indicate that both the Leu and Val substitutions for Ile 573 can confer the six-helix bundle fold. In contrast, the Pro and Ser mutations each essentially disrupt the trimeric complex formation. Moreover, Ala 573 maintains trimerization specificity at the expense of stability. Thus, the folding and stability of the N34(L6)C28 mutant peptides correlate well with severity of the in vivo phenotypes observed in cells expressing the full-length HIV-1 envelope protein complex. These results strongly suggest that the core structure formed by N34(L6)C28 plays a direct role in the membrane fusion step of HIV-1 infection.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 2.   Summary of CD and sedimentation equilibrium data for the I573 mutants

Many viral membrane fusion proteins can adopt two different tertiary folds. This structural polymorphism is the basis for conformational changes in response to environmental signals and ligand binding. The influenza virus hemagglutinin (HA) protein, for example, irreversibly switches from the native structure to the fusogenic conformation when exposed to a low pH (17, 18, 33, 41). Recent studies suggest that HA is most stable in its fusogenic state, while HA in its native state is metastable and thus has the potential to transform to a more stable, fusogenic state (1, 4, 5, 10). According to this hypothesis, membrane fusion is regulated by the conformational state of the HA protein.

Mutations within the N heptad repeat region of gp41 abolish membrane fusion activity without preventing formation of the native HIV-1 envelope protein complex (3, 11, 14, 38). These results can be reconciled by the hypothesis that these mutations do not disrupt the native structure of gp41 but do inhibit its conformational change to the fusion-active state (9, 38). This view is supported by our finding that fusion-defective mutations lead to great destabilization of the fusion-active core structure of gp41. In principle, introducing mutations into the N heptad repeat region of the gp41 ectodomain could shift the conformational equilibrium between the native and fusogenic folds, thereby allowing the native structure to be trapped in a metastable state for biophysical and structural studies.

N34(L6)C28 inhibits HIV-1 fusion. Peptides corresponding to the N- and C-terminal heptad repeat regions of the gp41 ectodomain exhibit antiviral activity and block membrane fusion (21, 37, 40). Although the mechanism of action of these peptide inhibitors is not known, considerable evidence suggests that they work, in a dominant-negative manner, by associating with gp41 during the fusion process (9, 15, 23, 27, 30, 31, 39). Since even the smaller N-36 and C-34 complex is too stable to be disrupted by peptide binding, one anticipates that only during the gp41 conformational change to the fusion-active state are the targets for the peptides available (reviewed in reference 7). A recent study of the structure of the ectodomain of simian immunodeficiency virus gp41 challenges this assumption (2).

The inhibitory activities of N34(L6)C28 and variants thereof were determined by an HIV-1 envelope glycoprotein-mediated cell-cell fusion assay as previously described (27). Cells expressing HIV-1 envelope glycoprotein (CHO[HIVe]) (clone 7d2) cells were a generous gift from M. Krieger, and MT-2 cells were obtained through the National Institutes of Health AIDS Research and Reference Reagent Program. CHO[HIVe] cells were plated at 2 × 104 cells/well in a 48-well dish and were grown for 24 h. Then, 105 MT-2 cells were added in the presence of various peptide concentrations. After 14 h of incubation at 37°C, syncytia were counted by microscopic examination at a magnification of 40×.

The N-51 and C-43 complex is also capable of inhibiting fusion, with a 90% inhibitory concentration (IC90) of 1.5 µM (27). Due to difficulties in preparing stoichiometric amounts of the two peptides, this activity was originally believed to be caused by a small fraction of the dissociated C-43 peptide, because the isolated C-43 peptide is an effective inhibitor, with an IC90 of 0.14 µM (27). The single-chain N34(L6)C28 model folds into an extremely stable, six-helix bundle (Fig. 2B). This molecule thus offers an excellent model for investigating the inhibition mechanism of the gp41 core. We examined the relative abilities of N34(L6)C28 and the isolated N-34 and C-28 peptides to block syncytium formation between CHO[HIVe] cells and CD4+ target cells (MT-2). Figure 4 shows the inhibition of syncytium formation by N34(L6)C28, N-34, and C-28. N34(L6)C28 and C-28 have similar inhibitory activities, with IC90s of 2.0 and 1.3 µM, respectively, whereas the inhibitory activity of the N-34 peptide cannot be detected below concentrations of 3 µM.


View larger version (22K):
[in this window]
[in a new window]
  		FIG. 4.   Inhibition of syncytium formation. Inhibition of syncytium formation between CHO[HIVe] cells and CD4+ MT-2 cells by the isolated N-34 (open triangles) and C-28 (open squares) peptides and the N34(L6)C28 model peptide (open circles). Standard deviations of the means for triplicate samples are indicated by vertical bars.

Several lines of evidence suggest that the dissociated C-28 region is unlikely to account for the inhibitory activity of N34(L6)C28. First, the trimeric N34(L6)C28 complex is highly thermostable under physiological conditions, with a melting temperature of 63°C for a 2 µM solution in PBS. Second, the N34(L6)C28 core is highly resistant to trypsin digestion. Following the incubation of 1 mg of N34(L6)C28 with 0.01 mg of L-(tosylamido-2-phenyl)ethyl chloromethyl ketone-treated bovine trypsin at 37°C for 24 h in PBS, more than 90% of the molecules are still in an alpha -helical conformation, as judged by CD spectra. Trypsin cleaves N34(L6)C28 at two Arg residues in the six-residue linker region, as identified by mass spectrometry. This resistance was expected because the N-34 and C-28 complex was originally identified by limited proteolysis. Third, the inhibitory activity of N34(L6)C28 was not affected even in the presence of 10 µM of the isolated N-34 peptide. If the inhibitory activity of N34(L6)C28 is due to a small fraction of the dissociated C-28, the addition of N-34 should decrease the core's activity by associating with the C-28 region. Taken together, our results suggest that in the N34(L6)C28 model of the gp41 core, membrane fusion is inhibited via a mechanism different from that in the dominant-negative model proposed for the isolated N and C peptides. For example, the fusion-active six-helix bundle may act as an inhibitor by interfering with the formation of a fusion pore (36). Understanding the inhibition mechanism of the gp41 core will provide insights into the HIV-1 entry process and could offer new perspectives in the search for effective antiviral therapies.


    ACKNOWLEDGMENTS

We thank Neville Kallenbach for critical reading of the manuscript.

This work was supported by the start-up fund from Weill Medical College of Cornell University and by NIH grant AI 42382.


    FOOTNOTES

* Corresponding author. Mailing address: Department of Biochemistry, Weill Medical College of Cornell University, 1300 York Ave., New York, NY 10021. Phone: (212) 746-6562. Fax: (212) 746-8875. E-mail: mlu{at}mail.med.cornell.edu.


    REFERENCES
Top
Abstract
Text
References

1. Bullough, P. A., F. M. Hughson, J. J. Skehel, and D. C. Wiley. 1994. Structure of influenza hemagglutinin at the pH of membrane fusion. Nature 371:37-43[Medline].
2. Caffrey, M., M. Cai, J. Kaufman, S. J. Stahl, P. T. Wingfield, D. G. Covell, A. M. Groneborn, and G. M. Clore. 1998. Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41. EMBO J. 17:4572-4584[Medline].
3. Cao, J., L. Bergeron, E. Helseth, M. Thali, H. Repke, and J. Sodroski. 1993. Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J. Virol. 67:2747-2755[Abstract/Free Full Text].
4. Carr, C. M., and P. S. Kim. 1993. A spring-loaded mechanism for the conformational change of influenza hemagglutinin. Cell 73:823-832[Medline].
5. Carr, C. M., C. Chaudhry, and P. S. Kim. 1997. Influenza hemagglutinin is spring-loaded by a metastable native conformation. Proc. Natl. Acad. Sci. USA 94:14306-14313[Abstract/Free Full Text].
6. Chambers, P., C. R. Pringle, and A. J. Easton. 1990. Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins. J. Gen. Virol. 71:3075-3080[Abstract/Free Full Text].
7. Chan, D. C., and P. S. Kim. 1998. HIV entry and its inhibition. Cell 93:681-684[Medline].
8. Chan, D. C., D. Fass, J. M. Berger, and P. S. Kim. 1997. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263-273[Medline].
9. Chen, C.-H., T. J. Matthews, C. B. McDanal, D. P. Bolognesi, and M. L. Greenberg. 1995. A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. J. Virol. 69:3771-3777[Abstract].
10. Chen, J., S. A. Wharton, W. Weissenhorn, L. J. Calder, F. M. Hughson, J. J. Skehel, and D. C. Wiley. 1994. A soluble domain of the membrane-anchoring chain of influenza virus hemagglutinin (HA2) folds in Escherichia coli into the low-pH-induced conformation. Proc. Natl. Acad. Sci. USA 92:12205-12209[Abstract/Free Full Text].
11. Chen, S. S.-L., C.-N. Lee, W.-R. Lee, K. McIntosh, and T.-H. Lee. 1993. Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein. J. Virol. 67:3615-3619[Abstract/Free Full Text].
12. Delwart, E. J., G. Mosialos, and T. Gilmore. 1990. Retroviral envelope glycoproteins contain a leucine zipper like repeat. AIDS Res. Hum. Retroviruses 6:703-706[Medline].
13. Dimitrov, D. S. 1997. How do viruses enter cells? The HIV coreceptors teach us a lesson of complexity. Cell 91:721-730[Medline].
14. Dubay, J. W., S. J. Roberts, B. Brody, and E. Hunter. 1992. Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity. J. Virol. 66:4748-4756[Abstract/Free Full Text].
15. Furuta, R. A., C. T. Wild, Y. Weng, and C. D. Weiss. 1998. Capture of an early fusion-active conformation of HIV-1 gp41. Nat. Struct. Biol. 5:276-279[Medline].
16. Gallaher, W. R., J. M. Ball, R. F. Garry, M. C. Griffin, and R. C. Montelaro. 1989. A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res. Hum. Retroviruses 5:431-440[Medline].
17. Hernandez, L. D., L. R. Hoffman, T. G. Wolfsberg, and J. M. White. 1996. Virus-cell and cell-cell fusion. Annu. Rev. Cell Dev. Biol. 12:627-661[Medline].
18. Hughson, F. M. 1995. Molecular mechanisms of protein-mediated membrane fusion. Curr. Opin. Struct. Biol. 5:507-513[Medline].
19. Hunter, E., and R. Swanstrom. 1990. Retrovirus envelope glycoprotein. Curr. Top. Microbiol. Immunol. 157:187-253[Medline].
20. Jiang, S., K. Lin, and M. Lu. 1998. A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. J. Virol. 72:10213-10217[Abstract/Free Full Text].
21. Jiang, S., K. Lin, N. Strick, and A. R. Neurath. 1993. HIV-1 inhibition by a peptide. Nature 365:113[Medline].
22. Johnson, M. L., J. J. Correia, D. A. Yphantis, and H. R. Halvorson. 1981. Analysis of data from the analytical ultracentrifuge by nonlinear least-squares techniques. Biophys. J. 36:575-588[Medline].
23. Judice, J. K., J. Y. K. Tom, W. Huang, T. Wrin, J. Vennari, C. J. Petropoulos, and R. S. McDowell. 1997. Inhibition of HIV type 1 infectivity by constrained alpha -helical peptides: implications for the viral fusion mechanism. Proc. Natl. Acad. Sci. USA 94:13426-13430[Abstract/Free Full Text].
24. Kwong, P. D., R. Wyatt, J. Robinson, R. W. Sweet, J. Sodroski, and W. A. Hendrickson. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659[Medline].
25. Laue, T. M., B. D. Shah, T. M. Ridgeway, and S. L. Pelletier. 1992. Computer-aided interpretation of analytical sedimentation data for proteins, p. 90-125. In S. E. Harding, A. J. Rowe, and J. C. Horton (ed.), Analytical ultracentrifugation in biochemistry and polymer science. Royal Society of Chemistry, Cambridge, England.
26. Lu, M., and P. S. Kim. 1997. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J. Biomol. Struct. Dyn. 15:465-471[Medline].
27. Lu, M., S. C. Blacklow, and P. S. Kim. 1995. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 2:1075-1082[Medline].
28. Luciw, P. A. 1996. Human immunodeficiency viruses and their replication, p. 1881-1952. In B. N. Fields, D. M. Knipe, P. M. Howley, R. M. Chanock, J. L. Melnick, T. P. Monath, B. Roizman, and S. E. Straus (ed.), Fields virology. Lippincott-Raven Publishers, Philadelphia, Pa.
29. Moore, J. P., B. A. Jameson, R. A. Weiss, and Q. J. Sattentau. 1993. The HIV-cell fusion reaction, p. 233-289. In J. Bentz (ed.), Viral fusion mechanisms. CRC Press, Inc., Boca Raton, Fla.
30. Munoz-Barroso, I., S. Durell, K. Sakaguchi, E. Appella, and R. Blumenthal. 1988. Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J. Cell Biol. 140:315-323[Abstract/Free Full Text].
31. Rimsky, L. T., D. C. Shugars, and T. J. Matthews. 1998. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 72:986-993[Abstract/Free Full Text].
32. Rizzuto, C. D., R. Wyatt, N. Hernandez-Ramos, Y. Sun, P. D. Kwong, W. A. Hendrickson, and J. A. Sodroski. 1998. Conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280:1949-1953[Abstract/Free Full Text].
33. Stegmann, T., and A. Helenius. 1993. Influenza virus fusion: from models toward a mechanism, p. 89-111. In J. Bentz (ed.), Viral fusion mechanisms. CRC Press, Boca Raton, Fla.
34. Tan, K., J. Liu, J. Wang, S. Shen, and M. Lu. 1997. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. USA 94:12303-12308[Abstract/Free Full Text].
35. Weissenhorn, W., A. Dessen, S. C. Harrison, J. J. Skehel, and D. C. Wiley. 1997. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387:426-430[Medline].
36. White, J. M. 1992. Membrane fusion. Science 258:917-924[Abstract/Free Full Text].
37. Wild, C. T., D. C. Shugars, T. K. Greenwell, C. B. McDanal, and T. J. Matthews. 1994. Peptides corresponding to a predictive alpha -helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. USA 91:9770-9774[Abstract/Free Full Text].
38. Wild, C. T., J. W. Dubay, T. K. Greenwell, T. Baird, Jr., T. G. Oas, C. B. McDanal, E. Hunter, and T. J. Matthews. 1994. Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc. Natl. Acad. Sci. USA 91:12676-12680[Abstract/Free Full Text].
39. Wild, C. T., T. Greenwell, D. Shugars, L. Rimsky-Clarke, and T. Matthews. 1995. The inhibitory activity of an HIV-1 type peptide correlates with its ability to interact with a leucine zipper structure. AIDS Res. Hum. Retroviruses 11:323-325[Medline].
40. Wild, C. T., T. Oas, C. B. McDanal, D. Bolognesi, and T. J. Matthews. 1992. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. USA 89:10537-10541[Abstract/Free Full Text].
41. Wiley, D. C., and J. J. Skehel. 1987. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu. Rev. Biochem. 56:365-394[Medline].
42. Wilkinson, D. 1996. HIV-1: cofactors provide the entry keys. Curr. Biol. 6:1051-1053[Medline].

Journal of Virology, May 1999, p. 4433-4438, Vol. 73, No. 5
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Eggink, D., Langedijk, J. P. M., Bonvin, A. M. J. J., Deng, Y., Lu, M., Berkhout, B., Sanders, R. W. (2009). Detailed Mechanistic Insights into HIV-1 Sensitivity to Three Generations of Fusion Inhibitors. J. Biol. Chem. 284: 26941-26950 [Abstract] [Full Text]  
  • He, Y., Liu, S., Jing, W., Lu, H., Cai, D., Chin, D. J., Debnath, A. K., Kirchhoff, F., Jiang, S. (2007). Conserved Residue Lys574 in the Cavity of HIV-1 Gp41 Coiled-coil Domain Is Critical for Six-helix Bundle Stability and Virus Entry. J. Biol. Chem. 282: 25631-25639 [Abstract] [Full Text]  
  • Huang, J.-H., Lu, L., Lu, H., Chen, X., Jiang, S., Chen, Y.-H. (2007). Identification of the HIV-1 gp41 Core-binding Motif in the Scaffolding Domain of Caveolin-1. J. Biol. Chem. 282: 6143-6152 [Abstract] [Full Text]  
  • Suntoke, T. R., Chan, D. C. (2005). The Fusion Activity of HIV-1 gp41 Depends on Interhelical Interactions. J. Biol. Chem. 280: 19852-19857 [Abstract] [Full Text]  
  • Trivedi, V. D., Cheng, S.-F., Wu, C.-W., Karthikeyan, R., Chen, C.-J., Chang, D.-K. (2003). The LLSGIV stretch of the N-terminal region of HIV-1 gp41 is critical for binding to a model peptide, T20. Protein Eng Des Sel 16: 311-317 [Abstract] [Full Text]  
  • Sanders, R. W., Vesanen, M., Schuelke, N., Master, A., Schiffner, L., Kalyanaraman, R., Paluch, M., Berkhout, B., Maddon, P. J., Olson, W. C., Lu, M., Moore, J. P. (2002). Stabilization of the Soluble, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1. J. Virol. 76: 8875-8889 [Abstract] [Full Text]  
  • Boutonnet, N., Janssens, W., Boutton, C., Verschelde, J.-L., Heyndrickx, L., Beirnaert, E., van der Groen, G., Lasters, I. (2002). Comparison of Predicted Scaffold-Compatible Sequence Variation in the Triple-Hairpin Structure of Human Immunodeficiency Virus Type 1 gp41 with Patient Data. J. Virol. 76: 7595-7606 [Abstract] [Full Text]  
  • Follis, K. E., Larson, S. J., Lu, M., Nunberg, J. H. (2002). Genetic Evidence that Interhelical Packing Interactions in the gp41 Core Are Critical for Transition of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein to the Fusion-Active State. J. Virol. 76: 7356-7362 [Abstract] [Full Text]  
  • Liu, J., Wang, S., Hoxie, J. A., LaBranche, C. C., Lu, M. (2002). Mutations That Destabilize the gp41 Core Are Determinants for Stabilizing the Simian Immunodeficiency Virus-CPmac Envelope Glycoprotein Complex. J. Biol. Chem. 277: 12891-12900 [Abstract] [Full Text]  
  • Lu, M., Stoller, M. O., Wang, S., Liu, J., Fagan, M. B., Nunberg, J. H. (2001). Structural and Functional Analysis of Interhelical Interactions in the Human Immunodeficiency Virus Type 1 gp41 Envelope Glycoprotein by Alanine-Scanning Mutagenesis. J. Virol. 75: 11146-11156 [Abstract] [Full Text]  
  • Krueger, D. K., Kelly, S. M., Lewicki, D. N., Ruffolo, R., Gallagher, T. M. (2001). Variations in Disparate Regions of the Murine Coronavirus Spike Protein Impact the Initiation of Membrane Fusion. J. Virol. 75: 2792-2802 [Abstract] [Full Text]  
  • Sanders, R. W., Schiffner, L., Master, A., Kajumo, F., Guo, Y., Dragic, T., Moore, J. P., Binley, J. M. (2000). Variable-Loop-Deleted Variants of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Can Be Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits. J. Virol. 74: 5091-5100 [Abstract] [Full Text]  
  • Weng, Y., Yang, Z., Weiss, C. D. (2000). Structure-Function Studies of the Self-Assembly Domain of the Human Immunodeficiency Virus Type 1 Transmembrane Protein gp41. J. Virol. 74: 5368-5372 [Abstract] [Full Text]  
  • Shu, W., Ji, H., Lu, M. (2000). Interactions between HIV-1 gp41 Core and Detergents and Their Implications for Membrane Fusion. J. Biol. Chem. 275: 1839-1845 [Abstract] [Full Text]  
  • Ji, H., Shu, W., Burling, F. T., Jiang, S., Lu, M. (1999). Inhibition of Human Immunodeficiency Virus Type 1 Infectivity by the gp41 Core: Role of a Conserved Hydrophobic Cavity in Membrane Fusion. J. Virol. 73: 8578-8586 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lu, M.
Right arrow Articles by Shen, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lu, M.
Right arrow Articles by Shen, S.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»